Search Results - "Dimery, Isaiah"

Retrospective Evaluation of the Clinical and Radiographic Risk Factors Associated With Severe Pulmonary Hemorrhage in First-Line Advanced, Unresectable Non–Small-Cell Lung Cancer Treated With Carboplatin and Paclitaxel Plus Bevacizumab by SANDLER, Alan B, SCHILLER, Joan H, GRAY, Robert, DIMERY, Isaiah, BRAHMER, Julie, SAMANT, Meghna, WANG, Lisa I, JOHNSON, David H

“…Severe (grade >or= 3) pulmonary hemorrhage (PH) in advanced non-small-cell lung cancer was observed in two prospective, randomized, phase II (N = 99) and phase…”
Get full text

Comparison of Fulvestrant Versus Tamoxifen for the Treatment of Advanced Breast Cancer in Postmenopausal Women Previously Untreated With Endocrine Therapy: A Multinational, Double-Blind, Randomized Trial by HOWELL, Anthony, ROBERTSON, John F. R, OSBORNE, C. Kent, ABRAM, Paul, LICHINITSER, Mikhail R, ELLEDGE, Richard, BAJETTA, Emilio, WATANABE, Toru, MORRIS, Charles, WEBSTER, Alan, DIMERY, Isaiah

“…To evaluate the efficacy and tolerability of fulvestrant (Faslodex; AstraZeneca Pharmaceuticals LP, Wilmington, DE), a new estrogen receptor (ER) antagonist…”
Get full text

Clinical Implications and Translation of an Off-Target Pharmacology Profiling Hit: Adenosine Uptake Inhibition In Vitro by Amouzadeh, Hamid R., Dimery, Isaiah, Werner, Jonathan, Ngarmchamnanrith, Gataree, Engwall, Michael J, Vargas, Hugo M., Arrindell, Deborah

“…Off-target activities of drug candidates observed during in vitro pharmacological profiling frequently do not translate to adverse events (AEs) in human. This…”
Get full text

ZD6474, a Novel Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor, Inhibits Tumor Growth of Multiple Nervous System Tumors by RICH, Jeremy N, SATHORNSUMETEE, Sith, REARDON, David A, RYAN, Anderson J, WHEELER, Catherine, DIMERY, Isaiah, BIGNER, Darell D, FRIEDMAN, Henry S, KEIR, Stephen T, KIERAN, Mark W, LAFORME, Andrea, KAIPAINEN, Arja, MCLENDON, Roger E, GRANER, Michael W, AHMED RASHEED, B. K, LING WANG

“…Purpose: Primary central nervous system (CNS) tumors represent a diverse group of tumor types with heterogeneous molecular mechanisms that underlie their…”
Get full text

Prevention of Second Primary Tumors with Isotretinoin in Squamous-Cell Carcinoma of the Head and Neck by Hong, Waun KI, Lippman, Scott M, Itri, Loretta M, Karp, Daniel D, Lee, Jin S, Byers, Robert M, Schantz, Stimson P, Kramer, Alan M, Lotan, Reuben, Peters, Lester J, Dimery, Isaiah W, Brown, Barry W, Goepfert, Helmuth

“…Cancers of the lung, esophagus, and head and neck are expected to account for nearly one third of the 500,000 deaths due to cancer that have been predicted to…”
Get full text

Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma by Noy, Ariela, de Vos, Sven, Thieblemont, Catherine, Martin, Peter, Flowers, Christopher R., Morschhauser, Franck, Collins, Graham P., Ma, Shuo, Coleman, Morton, Peles, Shachar, Smith, Stephen, Barrientos, Jacqueline C., Smith, Alina, Munneke, Brian, Dimery, Isaiah, Beaupre, Darrin M., Chen, Robert

“…Marginal zone lymphoma (MZL) is a heterogeneous B-cell malignancy for which no standard treatment exists. MZL is frequently linked to chronic infection, which…”
Get full text

13-cis-retinoic acid in the treatment of oral leukoplakia by Hong, W K, Endicott, J, Itri, L M, Doos, W, Batsakis, J G, Bell, R, Fofonoff, S, Byers, R, Atkinson, E N, Vaughan, C

“…13-cis-Retinoic acid has been reported to be effective in treating oral leukoplakia. We randomly assigned 44 patients with this disease to receive…”
Get more information

A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors by Hong, David, Rasco, Drew, Veeder, Michael, Luke, Jason J, Chandler, Jason, Balmanoukian, Ani, George, Thomas J, Munster, Pamela, Berlin, Jordan D, Gutierrez, Martin, Mita, Alain, Wakelee, Heather, Samakoglu, Selda, Guan, Shanhong, Dimery, Isaiah, Graef, Thorsten, Borazanci, Erkut

“…Ibrutinib, a first-in-class, once-daily inhibitor of Bruton's tyrosine kinase, is approved in the United States for the treatment of various B-cell…”
Get more information

Phase II Study of Irinotecan Plus Cisplatin in Patients With Advanced Non–Small-Cell Lung Cancer by DEVORE, R. F, JOHNSON, D. H, MILLER, L. L, CRAWFORD, J, GARST, J, DIMERY, I. W, ECKARDT, J, ECKHARDT, S. G, ELFRING, G. L, SCHAAF, L. J, HANOVER, C. K

“…To evaluate the antitumor efficacy and safety of a combination of irinotecan (CPT-11) and cisplatin in patients with inoperable non-small-cell lung cancer…”
Get full text

Implantation metastasis of carcinoma after percutaneous fine-needle aspiration biopsy by Voravud, N, Shin, D M, Dekmezian, R H, Dimery, I, Lee, J S, Hong, W K

“…Implantation of malignant cells along the needle tract is an extremely rare but potential complication following percutaneous needle aspiration biopsy of…”
Get more information

A multicenter study of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib plus durvalumab in patients with relapsed/refractory (R/R) solid tumors by Hong, David S., Rasco, Drew W., Veeder, Michael H., Luke, Jason J., Chandler, Jason, Balmanoukian, Ani Sarkis, George, Thomas J., Munster, Pamela, Berlin, Jordan, Gutierrez, Martin, Mita, Alain C., Wakelee, Heather A., Samakoglu, Selda, Guan, Shanhong, Dimery, Isaiah W., Borazanci, Erkut

“…Abstract only…”
Get full text

Abstract B42: Ibrutinib in combination with durvalumab (MEDI4736) in patients with relapsed or refractory HER2-positive or triple-negative breast cancer: A phase 1b/2 multicenter study by Rasco, Drew W., Borazanci, Erkut, Guiterrez, Martin, Hong, David, Tawashi, Ahmed, Lin, Jennifer, Dimery, Isaiah W., Fosdale, Mark

“…Abstract Purpose: HER2+ and triple-negative (TN) breast cancers (BC) are associated with an aggressive course and poor prognosis, with currently available…”
Get full text

Ibrutinib + durvalumab (MEDI4736) in patients (pts) with relapsed or refractory (R/R) pancreatic adenocarcinoma (PAC): A phase Ib/II multicenter study by Borazanci, Erkut Hasan, Hong, David S., Gutierrez, Martin, Rasco, Drew W., Reid, Tony R., Veeder, Michael H., Tawashi, Ahmed, Lin, Jennifer, Dimery, Isaiah W.

“…Abstract only TPS484 Background: PAC is an aggressive disease characterized by poor prognosis and is inadequately treated with available therapies. Ibrutinib…”
Get full text

Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study by Noy, Ariela, de Vos, Sven, Thieblemont, Catherine, Martin, Peter, Flowers, Christopher, Morschhauser, Franck, Collins, Graham P., Ma, Shuo, Coleman, Morton, Peles, Shachar, Smith, Stephen, Smith, Alina, Munneke, Brian, Dimery, Isaiah, Beaupre, Darrin, Chen, Robert W

“…▪ Background: Marginal zone lymphoma (MZL) accounts for approximately 10% of cases of non-Hodgkin's lymphoma (NHL). Rituximab in combination with chemotherapy…”
Get full text

Ibrutinib Therapy in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Analysis By Prior Rituximab Treatment and Baseline Mutations by Chen, Robert, de Vos, Sven, Thieblemont, Catherine, Martin, Peter, Flowers, Christopher, Morschhauser, Franck, Collins, Graham, Ma, Shuo, Coleman, Morton, Peles, Shachar, Smith, Stephen D., Barrientos, Jacqueline C., Smith, Alina, Munneke, Brian, Wu, Shiquan, Cheung, Leo, Kwei, Kevin, Samakoglu, Selda, Arango-Hisijara, Israel, Dimery, Isaiah, Noy, Ariela

“…Background: Marginal zone lymphoma (MZL) is a group of indolent B-cell lymphomas that accounts for ~10% of non-Hodgkin's lymphomas (NHLs) in the US. Ibrutinib…”
Get full text

ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy by Frederick, Barbara, Gustafson, Dan, Bianco, Cataldo, Ciardiello, Fortunato, Dimery, Isaiah, Raben, David

“…Radiation enhances both epithelial growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) expression, which are a part of key pathways for…”
Get more information

Camptothecin and its analogs. An overview of their potential in cancer therapeutics by Muggia, F M, Dimery, I, Arbuck, S G

“…From the outset of their clinical testing the camptothecins have shown antitumor activity against gastrointestinal cancer. With the definition of mechanism of…”
Get more information

Superselective intra-arterial chemotherapy of advanced paranasal sinus tumors by Lee, Y Y, Dimery, I W, Van Tassel, P, De Pena, C, Blacklock, J B, Goepfert, H

“…Twenty-four patients with advanced paranasal sinus tumors were treated with combined superselective intra-arterial and systemic chemotherapy, yielding an…”
Get more information

Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancer by Schwartz, Gary K, Bertino, Joseph, Kemeny, Nancy, Saltz, Leonard, Kelsen, David K, Tong, William, Welch, Mary, Endres, Sandra, Dimery, Isaiah

“…Our objective was to determine the maximum tolerated dose (MTD) of sequential raltitrexed (Tomudex) and 5-fluorouracil (5-FU) by bolus administration every 3…”
Get full text

Estrogen receptors in normal salivary gland and salivary gland carcinoma by Dimery, I W, Jones, L A, Verjan, R P, Raymond, A K, Goepfert, H, Hong, W K

“…To access for possible hormone dependence, 19 samples of normal salivary gland tissue and 14 samples of salivary gland carcinoma were quantitatively analyzed…”
Get more information